亚宝药业集团股份有限公司 关于股份回购进展公告

Group 1 - The company has approved a share repurchase plan at the 2024 annual general meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of July 31, 2025, the company has repurchased a total of 200,000 shares, accounting for 0.03% of the total share capital, with a total payment of RMB 1,260,000 at a maximum and minimum transaction price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure [2]